Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Oct 28, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how certain cancer treatments that may harm the heart—known as cardiotoxic therapies—affect the heart health of adult patients with cancer. The researchers want to find out which patient characteristics might increase the risk of heart problems caused by these treatments. They are also looking for ways to identify heart issues early on, using tests and evaluations recommended by heart specialists.

To participate in this study, you must be at least 18 years old and currently receiving potentially harmful cancer treatments. Researchers will monitor your heart health over a period of two years through regular check-ups and tests, including blood tests and heart scans. This ongoing evaluation will help doctors better understand how to manage heart health in cancer patients and may lead to improved care for those undergoing similar treatments in the future. If you have any concerns or want to know more about participating, please talk to your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over the age of 18 at the time of evaluation
• • Patients treated with potentially cardiotoxic anticancer drugs
• • Patients for which complete clinical, electrocardiographic and echocardiographic data are available at first evaluation and at least at one follow-up visit.
• Exclusion Criteria:
• • Patients under the age of 18 at the time of evaluation
• • Patients whose documentation of the first visit is not available
• • Patients for whom it is not possible to obtain follow-up information through a medical visit or by telephone
• • Patient with poor acoustic window for echocardiographic examination.
• • Refusal of informed consent to participate in the study.